Does the media favor MIST or CRMD?

In the previous week, CorMedix had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled CorMedix'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MIST or DSGN more profitable?

Design Therapeutics' return on equity of -33.07% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -339.33% -61.79% Design Therapeutics N/A -33.07% -31.29%

Does the media prefer TLRY or MIST?

In the previous week, Tilray Brands had 15 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 16 mentions for Tilray Brands and 1 mentions for Milestone Pharmaceuticals. Tilray Brands' average media sentiment score of 0.50 beat Milestone Pharmaceuticals' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 6 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MIST or PRME?

In the previous week, Prime Medicine had 4 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Prime Medicine and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled Prime Medicine'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACRS or MIST?

In the previous week, Aclaris Therapeutics had 14 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 15 mentions for Aclaris Therapeutics and 1 mentions for Milestone Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 1.25 beat Milestone Pharmaceuticals' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Milestone Pharmaceuticals (MIST) Competitors

$1.23 0.00 (0.00%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$1.24 +0.01 (+0.57%)

As of 06:24 AM Eastern

Compare

MIST vs. CRMD, DSGN, TLRY, PRME, and ACRS

Should you buy Milestone Pharmaceuticals stock or one of its competitors? MarketBeat compares Milestone Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Milestone Pharmaceuticals include CorMedix (CRMD), Design Therapeutics (DSGN), Tilray Brands (TLRY), Prime Medicine (PRME), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

How does Milestone Pharmaceuticals compare to CorMedix?

Milestone Pharmaceuticals (NASDAQ:MIST) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Milestone Pharmaceuticals currently has a consensus target price of $7.25, suggesting a potential upside of 489.43%. CorMedix has a consensus target price of $15.00, suggesting a potential upside of 75.64%. Given Milestone Pharmaceuticals' higher probable upside, equities research analysts clearly believe Milestone Pharmaceuticals is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, CorMedix had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled CorMedix'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix has a net margin of 45.25% compared to Milestone Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
CorMedix	45.25%	45.57%	24.76%

Milestone Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

CorMedix has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A
CorMedix	$311.71M	2.15	$163.05M	$2.13	4.01

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CorMedix beats Milestone Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Design Therapeutics?

Milestone Pharmaceuticals (NASDAQ:MIST) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Milestone Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

In the previous week, Milestone Pharmaceuticals had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 1 mentions for Milestone Pharmaceuticals and 0 mentions for Design Therapeutics. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled Design Therapeutics'average media sentiment score.

Company	Overall Sentiment
Milestone Pharmaceuticals	Neutral
Design Therapeutics	Neutral

Design Therapeutics' return on equity of -33.07% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Design Therapeutics	N/A	-33.07%	-31.29%

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 19.5% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 17.1% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Milestone Pharmaceuticals has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Milestone Pharmaceuticals presently has a consensus target price of $7.25, indicating a potential upside of 489.43%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 57.74%. Given Milestone Pharmaceuticals' higher probable upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Milestone Pharmaceuticals beats Design Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Tilray Brands has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Tilray Brands presently has a consensus target price of $11.50, indicating a potential upside of 128.63%. Milestone Pharmaceuticals has a consensus target price of $7.25, indicating a potential upside of 489.43%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Milestone Pharmaceuticals has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by company insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Milestone Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.71	-$2.19B	-$13.65	N/A
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A

In the previous week, Tilray Brands had 15 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 16 mentions for Tilray Brands and 1 mentions for Milestone Pharmaceuticals. Tilray Brands' average media sentiment score of 0.50 beat Milestone Pharmaceuticals' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	6 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Milestone Pharmaceuticals beats Tilray Brands on 9 of the 16 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Prime Medicine?

Milestone Pharmaceuticals (NASDAQ:MIST) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Milestone Pharmaceuticals has higher earnings, but lower revenue than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A
Prime Medicine	$4.63M	115.47	-$201.14M	-$1.23	N/A

Milestone Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 16.0% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Milestone Pharmaceuticals currently has a consensus price target of $7.25, indicating a potential upside of 489.43%. Prime Medicine has a consensus price target of $7.65, indicating a potential upside of 158.45%. Given Milestone Pharmaceuticals' higher possible upside, research analysts clearly believe Milestone Pharmaceuticals is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Prime Medicine had 4 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Prime Medicine and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled Prime Medicine'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Milestone Pharmaceuticals has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Prime Medicine's return on equity of -188.82% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Summary

Milestone Pharmaceuticals and Prime Medicine tied by winning 7 of the 14 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Milestone Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Milestone Pharmaceuticals has lower revenue, but higher earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	77.77	-$64.92M	-$0.56	N/A
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A

In the previous week, Aclaris Therapeutics had 14 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 15 mentions for Aclaris Therapeutics and 1 mentions for Milestone Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 1.25 beat Milestone Pharmaceuticals' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclaris Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 163.76%. Milestone Pharmaceuticals has a consensus target price of $7.25, suggesting a potential upside of 489.43%. Given Milestone Pharmaceuticals' higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Aclaris Therapeutics beats Milestone Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Milestone Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIST vs. The Competition

Export

Metric	Milestone Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$153.13M	$3.34B	$6.48B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	-1.81	18.61	23.69	23.74
Price / Sales	98.80	296.90	512.55	110.46
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	3.15	8.04	10.46	6.78
Net Income	-$63.06M	$23.89M	$3.57B	$337.51M
7 Day Performance	-6.82%	-3.28%	0.25%	-2.34%
1 Month Performance	-35.94%	2.78%	3.24%	1.88%
1 Year Performance	-29.71%	36.03%	22.21%	25.55%

Milestone Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIST Milestone Pharmaceuticals	2.1622 of 5 stars	$1.23 flat	$7.25 +489.4%	-28.9%	$153.13M	$1.55M	N/A	30	Gap Up
CRMD CorMedix	2.6014 of 5 stars	$8.45 +0.1%	$15.00 +77.5%	-38.9%	$662.13M	$311.71M	3.97	30
DSGN Design Therapeutics	2.1367 of 5 stars	$10.44 -0.4%	$16.50 +58.0%	+160.8%	$654.55M	N/A	N/A	40
TLRY Tilray Brands	3.5287 of 5 stars	$5.49 -0.4%	$11.50 +109.5%	+24.0%	$642.19M	$210.48M	N/A	2,842
PRME Prime Medicine	1.7136 of 5 stars	$3.40 -4.2%	$7.65 +125.0%	N/A	$641.19M	$4.63M	N/A	N/A	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIST) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. CRMD, DSGN, TLRY, PRME, and ACRS

How does Milestone Pharmaceuticals compare to CorMedix?

Summary

How does Milestone Pharmaceuticals compare to Design Therapeutics?

Summary

How does Milestone Pharmaceuticals compare to Tilray Brands?

Summary

How does Milestone Pharmaceuticals compare to Prime Medicine?

Summary

How does Milestone Pharmaceuticals compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. CRMD, DSGN, TLRY, PRME, and ACRS

How does Milestone Pharmaceuticals compare to CorMedix?

Do analysts rate MIST or CRMD?

Does the media favor MIST or CRMD?

Is MIST or CRMD more profitable?

Which has more volatility & risk, MIST or CRMD?

Which has preferable valuation & earnings, MIST or CRMD?

Do institutionals & insiders hold more shares of MIST or CRMD?

Summary

How does Milestone Pharmaceuticals compare to Design Therapeutics?

Which has more risk & volatility, MIST or DSGN?

Does the media favor MIST or DSGN?

Is MIST or DSGN more profitable?

Do insiders & institutionals believe in MIST or DSGN?

Which has preferable earnings and valuation, MIST or DSGN?

Do analysts recommend MIST or DSGN?

Summary

How does Milestone Pharmaceuticals compare to Tilray Brands?

Which has more volatility & risk, TLRY or MIST?

Do analysts rate TLRY or MIST?

Is TLRY or MIST more profitable?

Do institutionals & insiders believe in TLRY or MIST?

Which has stronger valuation & earnings, TLRY or MIST?

Does the media prefer TLRY or MIST?

Summary

How does Milestone Pharmaceuticals compare to Prime Medicine?

Which has better valuation and earnings, MIST or PRME?

Which has more risk and volatility, MIST or PRME?

Do institutionals and insiders believe in MIST or PRME?

Do analysts rate MIST or PRME?

Does the media favor MIST or PRME?

Is MIST or PRME more profitable?

Summary

How does Milestone Pharmaceuticals compare to Aclaris Therapeutics?

Is ACRS or MIST more profitable?

Do insiders and institutionals have more ownership in ACRS or MIST?

Which has more volatility & risk, ACRS or MIST?

Which has better valuation and earnings, ACRS or MIST?

Does the media prefer ACRS or MIST?

Do analysts prefer ACRS or MIST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools